World Journal of Gastrointestinal Oncology最新文献

{"title":"Controversies around the treatment of peritoneal metastases of colorectal cancer.","authors":"Francisco J Morera-Ocon, Clara Navarro-Campoy, Ticiano Guastella, Francisco Landete-Molina","doi":"10.4251/wjgo.v17.i1.100199","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.100199","url":null,"abstract":"<p><p>In this editorial we examine the article by Wu <i>et al</i> published in the <i>World Journal of Gastrointestinal Oncology</i>. Surgical resection for peritoneal metastases from colorectal cancer (CRC) has been gradually accepted in the medical oncology community. A randomized trial (PRODIGE 7) on cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) failed to prove any benefit of oxaliplatin in the overall survival of patients with peritoneal metastases from colorectal origin. Nevertheless, isolated systemic chemotherapy for CRC stage IV has demonstrated a reduced response in peritoneal metastases than that obtained in other metastatic sites such as the liver. Another tool is required in those patients to achieve more local control of the disease. Surgical groups in peritoneal surgery continue to use HIPEC in their procedures, using other agents than oxaliplatin for peritoneal cavity infusion, such as mitomycin C. These patients present with complex surgical issues to manage, and consequently a large burden of complications has to be anticipated. Therefore, identifying patients who will benefit from CRS with or without HIPEC would be of great interest.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"100199"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple liver metastases of unknown origin: A case report.","authors":"Ying-Jin Wang, Ze-Chuan Liu, Jian Wang, Yin-Mo Yang","doi":"10.4251/wjgo.v17.i1.100210","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.100210","url":null,"abstract":"<p><strong>Background: </strong>The liver is the most common site of digestive system tumor metastasis, but not all liver metastases can be traced back to the primary lesions. Although it is unusual, syphilis can impact the liver, manifesting as syphilitic hepatitis with inflammatory nodules, which might be misdiagnosed as metastasis.</p><p><strong>Case summary: </strong>This case report involves a 46-year-old female who developed right upper abdominal pain and intermittent low fever that persisted for more than three months. No definitive diagnosis of a tumor had been made in the past decades, but signs of multiple liver metastases were recognized after a computed tomography scan without evidence of primary lesions. With positive serological tests for syphilis and a biopsy of the liver nodules, a diagnosis of hepatic syphilis was made and confirmed with follow-up nodule reduction after anti-syphilis therapy.</p><p><strong>Conclusion: </strong>Clinicians must be aware of the possibility that syphilis can cause hepatic inflammatory masses, especially when liver metastasis is suspected without evidence of primary lesions. A definitive diagnosis should be established in conjunction with a review of the patient's medical history for accurate therapeutic intervention.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"100210"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiparameter magnetic resonance imaging-based radiomics model for the prediction of rectal cancer metachronous liver metastasis.","authors":"Zhi-Da Long, Xiao Yu, Zhi-Xiang Xing, Rui Wang","doi":"10.4251/wjgo.v17.i1.96598","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.96598","url":null,"abstract":"<p><strong>Background: </strong>The liver, as the main target organ for hematogenous metastasis of colorectal cancer, early and accurate prediction of liver metastasis is crucial for the diagnosis and treatment of patients. Herein, this study aims to investigate the application value of a combined machine learning (ML) based model based on the multiparameter magnetic resonance imaging for prediction of rectal metachronous liver metastasis (MLM).</p><p><strong>Aim: </strong>To investigate the efficacy of radiomics based on multiparametric magnetic resonance imaging images of preoperative first diagnosed rectal cancer in predicting MLM from rectal cancer.</p><p><strong>Methods: </strong>We retrospectively analyzed 301 patients with rectal cancer confirmed by surgical pathology at Jingzhou Central Hospital from January 2017 to December 2023. All participants were randomly assigned to the training or validation queue in a 7:3 ratio. We first apply generalized linear regression model (GLRM) and random forest model (RFM) algorithm to construct an MLM prediction model in the training queue, and evaluate the discriminative power of the MLM prediction model using area under curve (AUC) and decision curve analysis (DCA). Then, the robustness and generalizability of the MLM prediction model were evaluated based on the internal validation set between the validation queue groups.</p><p><strong>Results: </strong>Among the 301 patients included in the study, 16.28% were ultimately diagnosed with MLM through pathological examination. Multivariate analysis showed that carcinoembryonic antigen, and magnetic resonance imaging radiomics were independent predictors of MLM. Then, the GLRM prediction model was developed with a comprehensive nomogram to achieve satisfactory differentiation. The prediction performance of GLRM in the training and validation queue was 0.765 [95% confidence interval (CI): 0.710-0.820] and 0.767 (95%CI: 0.712-0.822), respectively. Compared with GLRM, RFM achieved superior performance with AUC of 0.919 (95%CI: 0.868-0.970) and 0.901 (95%CI: 0.850-0.952) in the training and validation queue, respectively. The DCA indicated that the predictive ability and net profit of clinical RFM were improved.</p><p><strong>Conclusion: </strong>By combining multiparameter magnetic resonance imaging with the effectiveness and robustness of ML-based predictive models, the proposed clinical RFM can serve as an insight tool for preoperative assessment of MLM risk stratification and provide important information for individual diagnosis and treatment of rectal cancer patients.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"96598"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network pharmacology: Changes the treatment mode of \"one disease-one target\" in cancer treatment.","authors":"Shuai Liu, Yong-Wei Yu","doi":"10.4251/wjgo.v17.i1.101581","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.101581","url":null,"abstract":"<p><p>The article concluded that network pharmacology provides new ideas and insights into the molecular mechanism of traditional Chinese medicine (TCM) treatment of cancer. TCM is a new choice and hot spot in the field of cancer treatment. We have also previously published studies on TCM and network pharmacology. In this letter, we summarize the new paradigm of network pharmacology in cancer treatment mechanisms.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"101581"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-17A facilitates tumor progression <i>via</i> upregulating programmed death ligand-1 expression in hepatocellular carcinoma.","authors":"Zhong-Xia Yang, Li-Ting Zhang, Xiao-Jun Liu, Xue-Bin Peng, Xiao-Rong Mao","doi":"10.4251/wjgo.v17.i1.97831","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.97831","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is an inflammation-associated tumor with a dismal prognosis. Immunotherapy has become an important treatment strategy for HCC, as immunity is closely related to inflammation in the tumor microenvironment. Inflammation regulates the expression of programmed death ligand-1 (PD-L1) in the immunosuppressive tumor microenvironment and affects immunotherapy efficacy. Interleukin-17A (IL-17A) is involved in the remodeling of the tumor microenvironment and plays a protumor or antitumor role in different tumors. We hypothesized that IL-17A participates in tumor progression by affecting the level of immune checkpoint molecules in HCC.</p><p><strong>Aim: </strong>To investigate the effect and mechanism of action of IL-17A on PD-L1 expression and to identify attractive candidates for the treatment of HCC.</p><p><strong>Methods: </strong>The upregulation of PD-L1 expression in HCC cells by IL-17A was assessed by reverse transcription PCR, western blotting, and flow cytometry. Mechanistic studies were conducted with gene knockout models and pathway inhibitors. The function of IL-17A in immune evasion was explored through coculture of T cells and HCC cells. The effects of IL-17A on the malignant biological behaviors of HCC cells were evaluated <i>in vitro</i>, and the antitumor effects of an IL-17A inhibitor and its synergistic effects with a PD-L1 inhibitor were studied <i>in vivo</i>.</p><p><strong>Results: </strong>IL-17A upregulated PD-L1 expression in HCC cells in a dose-dependent manner, whereas IL-17A receptor knockout or treatment with a small mothers against decapentaplegic 2 inhibitor diminished the PD-L1 expression induced by IL-17A. IL-17A enhanced the survival of HCC cells in the coculture system. IL-17A increased the viability, G2/M ratio, and migration of HCC cells and decreased the apoptotic index. Cyclin D1, <i>VEGF</i>, <i>MMP9</i>, and <i>Bcl-1</i> expression increased after IL-17A treatment, whereas <i>BAX</i> expression decreased. The combination of IL-17A and PD-L1 inhibitors showed synergistic antitumor efficacy and increased cluster of differentiation 8 + T lymphocyte infiltration in an HCC mouse model.</p><p><strong>Conclusion: </strong>IL-17A upregulates PD-L1 expression <i>via</i> the IL-17A receptor/phosphorylation-small mothers against decapentaplegic 2 signaling pathway in HCC cells. Blocking IL-17A enhances the therapeutic efficacy of PD-L1 antibodies in HCC <i>in vivo</i>.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"97831"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective analysis of pathological types and imaging features in pancreatic cancer: A comprehensive study.","authors":"Yang-Gang Luo, Mei Wu, Hong-Guang Chen","doi":"10.4251/wjgo.v17.i1.99153","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.99153","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer remains one of the most lethal malignancies worldwide, with a poor prognosis often attributed to late diagnosis. Understanding the correlation between pathological type and imaging features is crucial for early detection and appropriate treatment planning.</p><p><strong>Aim: </strong>To retrospectively analyze the relationship between different pathological types of pancreatic cancer and their corresponding imaging features.</p><p><strong>Methods: </strong>We retrospectively analyzed the data of 500 patients diagnosed with pancreatic cancer between January 2010 and December 2020 at our institution. Pathological types were determined by histopathological examination of the surgical specimens or biopsy samples. The imaging features were assessed using computed tomography, magnetic resonance imaging, and endoscopic ultrasound. Statistical analyses were performed to identify significant associations between pathological types and specific imaging characteristics.</p><p><strong>Results: </strong>There were 320 (64%) cases of pancreatic ductal adenocarcinoma, 75 (15%) of intraductal papillary mucinous neoplasms, 50 (10%) of neuroendocrine tumors, and 55 (11%) of other rare types. Distinct imaging features were identified in each pathological type. Pancreatic ductal adenocarcinoma typically presents as a hypodense mass with poorly defined borders on computed tomography, whereas intraductal papillary mucinous neoplasms present as characteristic cystic lesions with mural nodules. Neuroendocrine tumors often appear as hypervascular lesions in contrast-enhanced imaging. Statistical analysis revealed significant correlations between specific imaging features and pathological types (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>This study demonstrated a strong association between the pathological types of pancreatic cancer and imaging features. These findings can enhance the accuracy of noninvasive diagnosis and guide personalized treatment approaches.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"99153"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial chemoembolization combined with lenvatinib and sintilimab <i>vs</i> lenvatinib alone in intermediate-advanced hepatocellular carcinoma.","authors":"Fei-Da Wu, Hai-Feng Zhou, Wei Yang, Di Zhu, Bi-Fei Wu, Hai-Bin Shi, Sheng Liu, Wei-Zhong Zhou","doi":"10.4251/wjgo.v17.i1.96267","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.96267","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most common form of liver cancer that has limited treatment options and a poor prognosis. Transarterial chemoembolization (TACE) is the first-line treatment for intermediate-stage HCC but can induce tumour hypoxia, thereby promoting angiogenesis. Recent studies suggested that combining TACE with anti-angiogenic therapies and immunotherapy might improve efficacy. Lenvatinib, a tyrosine kinase inhibitor, has demonstrated superior outcomes compared to sorafenib, while immune checkpoint inhibitors such as sintilimab show potential when combined with TACE. However, the efficacy and safety of TACE combined with lenvatinib and sintilimab (TACE + SL) compared to TACE with lenvatinib alone (TACE + L) in patients with intermediate-advanced HCC has not yet been investigated.</p><p><strong>Aim: </strong>To evaluate the efficacy and safety of TACE + SL therapy in comparison to TACE + L therapy in patients with intermediate-advanced HCC.</p><p><strong>Methods: </strong>A retrospective analysis was performed on patients with intermediate-advanced HCC who received TACE plus lenvatinib with or without sintilimab between September 2019 and September 2022. Baseline characteristics were compared, and propensity score matching was applied. Overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) were evaluated between the two groups, and adverse events were analyzed.</p><p><strong>Results: </strong>The study included 57 patients, with 30 in the TACE + SL group and 27 in the TACE + L group. The TACE + SL group demonstrated significantly improved median PFS and OS compared to the TACE + L group (PFS: 14.1 months <i>vs</i> 9.6 months, <i>P</i> = 0.016; OS: 22.4 months <i>vs</i> 14.1 months, <i>P</i> = 0.039), along with a higher ORR (70.0% <i>vs</i> 55.6%). After propensity score matching, 30 patients were included, with the TACE + SL group again showing longer median PFS and a trend toward improved OS (PFS: 14.6 months <i>vs</i> 9.2 months, <i>P</i> = 0.012; OS: 23.9 months <i>vs</i> 16.3 months, <i>P</i> = 0.063), and a higher ORR (73.3% <i>vs</i> 53.3%). No severe adverse events were reported.</p><p><strong>Conclusion: </strong>TACE + SL demonstrated superior outcomes in terms of OS and PFS, compared to TACE + L. These findings suggest that the addition of sintilimab might enhance the therapeutic response in patients with intermediate-advanced HCC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"96267"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlations of the expression of Cx43, SCF^FBXW7, p-cyclin E1 (Ser73), p-cyclin E1 (Thr77) and p-cyclin E1 (Thr395) in colon cancer tissues.","authors":"Rong-Gang Luan, Ming-Da Liu, Zi-Feng Deng, Cong-Lan Lu, Mei-Ling Yu, Ming-Yu Zhang, Rong Liu, Ran An, You-Liang Yao, Dong-Bei Guo, Yong-Xing Zhang, Lei Zhao","doi":"10.4251/wjgo.v17.i1.98410","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.98410","url":null,"abstract":"<p><strong>Background: </strong>Previous cellular studies have demonstrated that elevated expression of Cx43 promotes the degradation of cyclin E1 and inhibits cell proliferation through ubiquitination. Conversely, reduced expression results in a loss of this capacity to facilitate cyclin E degradation. The ubiquitination and degradation of cyclin E1 may be associated with phosphorylation at specific sites on the protein, with Cx43 potentially enhancing this process by facilitating the phosphorylation of these critical residues<b>.</b></p><p><strong>Aim: </strong>To investigate the correlation between expression of Cx43, SKP1/Cullin1/F-box (SCF)^FBXW7, p-cyclin E1 (ser73, thr77, thr395) and clinicopathological indexes in colon cancer.</p><p><strong>Methods: </strong>Expression levels of Cx43, SCF^FBXW7, p-cyclin E1 (ser73, thr77, thr395) in 38 clinical colon cancer samples were detected by immunohistochemistry and were analyzed by statistical methods to discuss their correlations.</p><p><strong>Results: </strong>Positive rate of Cx43, SCF^FBXW7, p-cyclin E1(Ser73), p-cyclin E1 (Thr77) and p-cyclin E1 (Thr395) in detected samples were 76.32%, 76.32%, 65.79%, 5.26% and 55.26% respectively. Positive expressions of these proteins were not related to the tissue type, degree of tissue differentiation or lymph node metastasis. Cx43 and SCF^FBXW7(<i>r</i> = 0.749), p-cyclin E1 (Ser73) (<i>r</i> = 0.667) and p-cyclin E1 (Thr395) (<i>r</i> = 0.457), SCF^FBXW7 and p-cyclin E1 (Ser73) (<i>r</i> = 0.703) and p-cyclin E1 (Thr395) (0.415) were correlated in colon cancer (<i>P</i> < 0.05), and expressions of the above proteins were positively correlated in colon cancer.</p><p><strong>Conclusion: </strong>Cx43 may facilitate the phosphorylation of cyclin E1 at the Ser73 and Thr195 sites through its interaction with SCF^FBXW7, thereby influencing the ubiquitination and degradation of cyclin E1.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"98410"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of gut microbiota dysbiosis in patients with colorectal polyps.","authors":"Xian-Rong Wu, Xiao-Hong He, Yong-Fang Xie","doi":"10.4251/wjgo.v17.i1.98872","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.98872","url":null,"abstract":"<p><p>This editorial, inspired by a recent study published in the <i>World Journal of Gastrointestinal Oncology</i>, covers the research findings on microbiota changes in various diseases. In recurrent colorectal polyps, the abundances of <i>Klebsiella</i>, <i>Parvimonas</i>, and <i>Clostridium</i> increase, while those of <i>Bifidobacterium</i> and <i>Lactobacillus</i> decrease. This dysbiosis may promote the formation and recurrence of polyps. Similar microbial changes have also been observed in colorectal cancer, inflammatory bowel disease, autism spectrum disorder, and metabolic syndrome, indicating the role of increased pathogens and decreased probiotics in these conditions. Regulating the gut microbiota, particularly by increasing probiotic levels, may help prevent polyp recurrence and promote gut health. This microbial intervention strategy holds promise as an adjunctive treatment for patients with colorectal polyps.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"98872"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a nomogram for overall survival in patients with esophageal carcinoma: A prospective cohort study in China.","authors":"Shi-Shi Yu, Xi Zheng, Xiao-Sheng Li, Qian-Jie Xu, Wei Zhang, Zhong-Li Liao, Hai-Ke Lei","doi":"10.4251/wjgo.v17.i1.96686","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.96686","url":null,"abstract":"<p><strong>Background: </strong>Esophageal carcinoma (EC) presents a significant public health issue in China, with its prognosis impacted by myriad factors. The creation of a reliable prognostic model for the overall survival (OS) of EC patients promises to greatly advance the customization of treatment approaches.</p><p><strong>Aim: </strong>To create a more systematic and practical model that incorporates clinically significant indicators to support decision-making in clinical settings.</p><p><strong>Methods: </strong>This study utilized data from a prospective longitudinal cohort of 3127 EC patients treated at Chongqing University Cancer Hospital between January 1, 2018, and December 12, 2020. Utilizing the least absolute shrinkage and selection operator regression alongside multivariate Cox regression analyses helped pinpoint pertinent variables for constructing the model. Its efficacy was assessed by concordance index (C-index), area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>Nine variables were determined to be significant predictors of OS in EC patients: Body mass index (BMI), Karnofsky performance status, TNM stage, surgery, radiotherapy, chemotherapy, immunotherapy, platelet-to-lymphocyte ratio, and albumin-to-globulin ratio (ALB/GLB). The model demonstrated a C-index of 0.715 (95%CI: 0.701-0.729) in the training cohort and 0.711 (95%CI: 0.689-0.732) in the validation cohort. In the training cohort, AUCs for 1-year, 3-year, and 5-year OS predictions were 0.773, 0.787, and 0.750, respectively; in the validation cohort, they were 0.772, 0.768, and 0.723, respectively, illustrating the model's precision. Calibration curves and DCA verified the model's predictive accuracy and net benefit.</p><p><strong>Conclusion: </strong>A novel prognostic model for determining the OS of EC patients was successfully developed and validated to help clinicians in devising individualized treatment schemes for EC patients.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"96686"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}